シェバ医療センター
| イスラエル | トルコ | オーストリア | |
| 白血病化学療法 | から $28,500 | から $8,000 | から $15,000 |
| 乳癌化学療法 | から $22,500 | から $1,200 | から $15,000 |
| CAR-T細胞療法 | から $84,000 | から $150,000 | から $350,000 |
| 治療的アフェレーシス | - | から $1,350 | - |
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Leukemia treatment in Israel is safe and follows international protocols. Facilities like Sheba Medical Center hold Joint Commission International accreditation. Specialized isolation units protect patients from infections. Multi-disciplinary teams manage clinical risks. Expert hematologists oversee advanced therapies like CAR T-cell and stem cell transplants.
Bookimed Expert Insight: Israeli centers demonstrate a high level of specialization in cellular therapies. Sheba Medical Center treats over 2 million patients annually and is a global leader in CAR-T programs. Dr. Ron Ram at Sourasky Medical Center has performed several hundred stem cell transplants. This high procedural volume typically translates to better management of complex treatment side effects. Patients should note that CAR T-cell therapy packages often include 21 days of hospitalization for close monitoring.
Patient Consensus: Patients note that medical care remains excellent, though they recommend checking travel advisories for geopolitical stability. Many emphasize the importance of English-speaking staff at major centers like Ichilov and Sheba for clear communication about side effects.
Israeli hematologists are highly qualified specialists who undergo over a decade of rigorous training. Experts like Dr. Michael Shapira and Dr. Ron Ram maintain full English proficiency. Most senior physicians completed fellowships at prestigious institutions in the United States or United Kingdom. This ensures clear communication for international patients.
Bookimed Expert Insight: Data shows a strong correlation between English proficiency and high-volume specialty procedures. Doctors like Dr. Polina Stepensky at Hadassah, who performed over 3,500 transplants, and Dr. Ron Ram, with several hundred stem-cell cases, frequently publish in international English journals. This link between clinical research and fluency means patients seeking advanced therapies like CAR-T often work with the most linguistically capable teams.
Patient Consensus: Patients note that while senior doctors are typically fluent, it is helpful to request an English-speaking coordination team for smoother communication with junior nursing staff. Those treated at JCI-accredited centers like Sheba or Sourasky report that language barriers rarely affect the quality of medical care.
International patients in Israel achieve a 90% average oncology success rate for leukemia. Top-tier centers like Sourasky and Sheba report survival outcomes that match or exceed global benchmarks. Specialized CAR T-cell therapy and advanced stem cell transplantations drive these high remission rates for complex blood cancers.
Bookimed Expert Insight: Data shows a significant price gap for identical CAR T-cell protocols in Israel. Packages at Sheba Medical Center are approximately $80,000, while Sourasky Medical Center (Ichilov) charges around $366,950. Both are Newsweek Top 10 hospitals, but Sourasky’s package includes longer 21-day hospitalization and 14-day hotel stays for recovery.
Patient Consensus: Patients note that international protocols in Israel are identical to those for locals, though costs are higher. Many emphasize that intensive monitoring in Israeli clinics helps maintain long-term remission after complex transplants.
Leukemia treatment in Israel typically requires a stay of 4 to 8 weeks for initial therapy and monitoring. Complex procedures like CAR T-cell therapy involve a 21-day hospital stay. Bone marrow transplants often necessitate 2 to 3 months in the country for recovery and isolation.
Bookimed Expert Insight: While most international patients expect long hospitalizations, our data shows a shift toward hybrid recovery. For instance, CAR T-cell packages at Sourasky Medical Center bundle 21 days in the hospital with 14 days in a nearby hotel. This suggests that clinics prioritize moving stable patients to a comfortable setting quickly. It reduces the feeling of being in a clinical environment while maintaining immediate access to specialists like Dr. Ron Ram.
Patient Consensus: Patients note that initial stays for ALL treatment often last 5 weeks and include lumbar punctures. Many emphasize the importance of coordinating with home-country doctors early to ensure a smooth handover after the first 3 months of intensive care.
Sheba Medical Center and Sourasky Medical Center are the most experienced Israeli hospitals for international bone marrow transplants. These JCI-accredited facilities perform hundreds of transplants annually. They utilize advanced CAR T-cell therapy and immunotherapy. Many specialists hold certifications from the American Society of Bone Marrow Transplantation.
Bookimed Expert Insight: Clinical leadership often dictates the procedure volume and success. For instance, Dr. Arnon Nagler at Sheba pioneered the first cord blood transplant in Israel. Meanwhile, Dr. Polina Stepensky at Hadassah has personally performed over 3,500 procedures. Patients should select clinics based on these specific physician caseloads rather than just general hospital rankings.
Patient Consensus: Patients frequently emphasize the necessity of securing a donor match before arriving in Israel to prevent treatment delays. Many note that larger centers like Sheba or Hadassah are better equipped for English-speaking international patients compared to smaller municipal hospitals.
Candidacy for CAR T-cell therapy in Israel depends on disease subtype, treatment history, and physical fitness. Patients typically require a relapsed or refractory diagnosis after two prior therapy lines. Eligibility also requires strong organ function and an ECOG performance status of 0 or 1.
Bookimed Expert Insight: Israeli centers like Sheba Medical Center often process CAR-T applications faster than European counterparts. While standard protocols suggest an age cap of 70, Israeli specialists frequently approve patients in their 80s if biological age and fitness are high. Dr. Arnon Nagler at Sheba and Dr. Ron Ram at Sourasky oversee programs with over 900 cases, often finding trial slots when commercial options are full.
Patient Consensus: Patients emphasize completing genetic mutation profiling and organ labs before the first consultation to speed up approval. Many note that treating minor infections early prevents sudden exclusion from time-sensitive clinical trial windows.
Post-discharge support for international leukemia patients in Israel focuses on detailed medical documentation and specialist consultations. Leading centers like Sheba Medical Center provide formal follow-up examinations and oncohematologist consultations within their treatment packages. This ensures a safe transition before patients return to their home countries.
Bookimed Expert Insight: While Israeli hospitals offer world-class CAR T-cell therapy and transplants, formal remote monitoring is often limited once you leave. Data shows Sheba Medical Center packages specifically bundle follow-up examinations into their $80,000 protocols. Patients should prioritize these inclusive packages to ensure they have a dedicated window for post-treatment stabilization before flying home. This gap between hospital discharge and your flight is the most critical time for catching delayed immune responses.
Patient Consensus: Patients note they must proactively arrange for their local oncologists to accept Israeli treatment plans before returning home. It is essential to request all medical records and medication names in English to avoid local pharmacy or treatment delays.
Israel offers advanced in-house CAR T-cell therapy with a 10-day manufacturing window. This is significantly faster than commercial options in Australia. Leading centres like Sheba Medical Center provide targeted cell therapies and trial-based protocols for complex relapsed or refractory cases.
Bookimed Expert Insight: Israeli oncology packages often combine treatment with extensive diagnostics like PET/CT and head MRI. Sheba Medical Center offers a CAR-T program for A$110,400 that includes 21 hospital days. This high-volume approach provides continuous monitoring that is rarely bundled in standard commercial therapies abroad.
Patient Consensus: Patients note Israel is most effective for complex, relapsed cases where speed of access is vital. Detailed medical records and pathology are essential before starting the time-intensive transplant or cellular therapy pathway.
Israeli hospitals report a 90% average success rate for leukaemia treatments. Paediatric survival for acute lymphoblastic leukaemia exceeds 90%, while advanced CAR T-cell therapy achieves 70–90% remission in resistant cases. Outcomes depend on subtype, age, and access to precision drugs and stem cell transplants.
Bookimed Expert Insight: Israel's leadership in CAR-T therapy stems from on-site manufacturing at centres like Sheba Medical Center. This lowers waiting times and costs, with paediatric immunotherapy packages starting around A$110,400. Australian patients benefit from this scale, as doctors like Dr Ron Ram have performed several hundred stem cell transplants.
Patient Consensus: Patients in Israel emphasise that successful remission requires fast molecular testing and expert teams. They note that the focus is on long-term monitoring and securing second opinions to tailor management plans effectively.
Patients can receive a medical consultation before travelling to Israel. Specialists conduct these via telehealth or email to review medical records and pathology results. This step confirms the treatment plan and provides clear cost estimates before patients depart for international care.
Bookimed Expert Insight: Israel ranks as a top destination for complex cases because its leading hospitals serve nearly 2,000,000 patients annually. Data shows that centres like Sheba Medical Center often include specialist consultations within their A$110,400 to A$220,800 leukaemia packages. These sessions are vital because they allow world-renowned experts to verify if advanced cellular immunotherapies are suitable before the patient flies.
Patient Consensus: Patients note it is essential to request a written treatment plan and detailed cost estimate during the initial remote session. They also suggest involving a local Australian haematologist to help coordinate follow-up care and ensure all medical records are consistent between countries.
Sheba Medical Center and Sourasky Medical Center are Israel's premier institutions for haemato-oncology. These JCI-accredited tertiary facilities lead the world in CAR-T cell immunotherapy and complex bone marrow transplants. They treat thousands of cases annually with 90% success rates in many oncology procedures.
Bookimed Expert Insight: Israeli haemato-oncology stands out because top specialists often hold triple board certifications in internal medicine, haematology, and oncology. Dr Ron Ram and Dr Avichai Shimoni are examples of experts with 30+ years of experience and hundreds of published studies. This academic depth ensures patients receive protocols refined by active clinical trial participation, which is vital for resistant leukaemia cases.
Patient Consensus: Patients note that major university-affiliated centres in Israel provide the most comprehensive specialist coverage. They suggest prioritizing hospitals with high transplant volumes rather than general reputation for the fastest access to complex cell therapies.
State hospitals in Israel are major academic centres equipped for complex leukemia treatments including CAR T-cell therapy and bone marrow transplants. While private clinics offer shorter wait times and superior amenities, state facilities like Sheba Medical Center provide critical intensive care support and in-house blood banks essential for managing intensive oncology cases.
Bookimed Expert Insight: While private care is faster, high-volume state hospitals in Israel often secure better outcomes for complex leukemia. Sheba Medical Center treats 2 million patients annually and ranks 7th worldwide. Facilities of this scale integrate research, diagnostics, and emergency backup that smaller private clinics cannot easily replicate. For Australian patients, this means choosing the facility infrastructure is just as important as selecting the individual specialist.
Patient Consensus: Patients note state hospitals are better for handling intensive care needs and emergencies during treatment in Israel. They highlight that speed and hotel-like comfort in private clinics are less important than having onsite transplant capabilities and 24-hour medical support.
Leukaemia care in Israel generally requires 4 to 12 weeks depending on the procedure. Diagnostic evaluations take 3 to 5 days. CAR T-cell therapy requires approximately 8 weeks. Bone marrow transplants demand a stay of 2 to 3 months for monitoring and recovery.
Bookimed Expert Insight: Israeli oncology centres like Sheba Medical Center and Sourasky Medical Center (Ichilov) are global leaders in CAR T-cell therapy. Some packages include up to 14 nights of hotel accommodation. This helps manage the outpatient monitoring phase without extra search for local stays.
Patient Consensus: Patients in Israel note that stays often extend beyond initial estimates until blood counts recover. It is essential to wait for clear haematology reviews before booking a return flight home.